FDC Ltd

₹ 330 1.88%

09 Oct - close price

About

FDC (Fairdeal Corporation) Ltd Limited (found in 1936) is among India’s leading fully integrated pharmaceutical companies. The Company is a pioneer in the manufacture of specialized formulations, and among the world’s foremost manufacturers and marketers of Oral Rehydration Salts (ORS). .^[1]

Key Points

Revenue Breakup FY25^[1]
Formulations: 92%,
Bulk Drugs : 6%,
Profit share - Formulation: 2%

Website BSE NSE

Market Cap ₹ 5,375 Cr.
Current Price ₹ 330
High / Low ₹ 474 / 313
Stock P/E 17.5
Book Value ₹ 153
Dividend Yield 1.51 %
ROCE 15.4 %
ROE 11.2 %
Face Value ₹ 1.00

Add ratio to table

Edit ratios

Pros

Company has reduced debt.
Company is almost debt free.
Company has been maintaining a healthy dividend payout of 19.8%

Cons

The company has delivered a poor sales growth of 10.3% over past five years.
Company has a low return on equity of 12.3% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	536	486	458	462	638	514	464	492	648	473	465	585	668
	414	410	374	406	492	444	417	438	508	439	412	478	525
Operating Profit	122	76	84	56	147	70	47	54	140	34	52	106	143
OPM %	23%	16%	18%	12%	23%	14%	10%	11%	22%	7%	11%	18%	21%
	29	27	25	20	28	35	19	16	36	21	0	50	48
Interest	1	1	1	1	1	1	1	1	1	1	1	2	1
Depreciation	10	10	10	10	11	14	13	16	15	15	15	14	15
Profit before tax	141	93	98	65	163	90	51	53	160	38	36	140	175
Tax %	22%	25%	19%	29%	27%	20%	28%	27%	24%	26%	22%	26%	24%
	110	70	79	46	119	72	37	39	121	28	28	103	132
EPS in Rs	6.62	4.29	4.87	2.84	7.31	4.42	2.28	2.38	7.45	1.74	1.74	6.35	8.14
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
	888	994	1,013	1,074	1,089	1,341	1,331	1,525	1,784	1,943	2,108	2,171	2,190
	690	765	769	841	860	1,038	997	1,271	1,533	1,604	1,783	1,825	1,855
Operating Profit	199	229	243	233	229	304	334	254	251	339	325	346	335
OPM %	22%	23%	24%	22%	21%	23%	25%	17%	14%	17%	15%	16%	15%
	46	39	44	45	42	57	95	76	50	102	91	93	118
Interest	2	1	1	1	1	3	3	3	4	4	5	5	5
Depreciation	39	34	35	35	33	37	38	37	39	40	54	59	59
Profit before tax	204	232	252	241	237	320	388	289	258	396	357	375	390
Tax %	27%	27%	25%	28%	28%	25%	22%	25%	25%	23%	25%	25%
	148	169	189	174	170	240	301	216	194	305	267	281	293
EPS in Rs	8.33	9.48	10.60	9.95	9.74	14.03	17.85	12.82	11.70	18.75	16.39	17.29	17.97
Dividend Payout %	27%	24%	21%	-0%	-0%	6%	-0%	-0%	-0%	-0%	31%	29%

Compounded Sales Growth
10 Years:	8%
5 Years:	10%
3 Years:	7%
TTM:	3%

Compounded Profit Growth
10 Years:	5%
5 Years:	-1%
3 Years:	12%
TTM:	14%

Stock Price CAGR
10 Years:	4%
5 Years:	-1%
3 Years:	-4%
1 Year:	-28%

Return on Equity
10 Years:	13%
5 Years:	12%
3 Years:	12%
Last Year:	11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	18	18	18	18	18	17	17	17	17	16	16	16
Reserves	919	1,065	1,252	1,259	1,428	1,530	1,717	1,940	1,965	2,081	2,265	2,469
	2	1	1	1	1	15	15	32	28	21	21	15
	210	182	197	228	194	250	208	281	333	350	412	418
Total Liabilities	1,148	1,266	1,468	1,505	1,640	1,813	1,956	2,270	2,343	2,468	2,714	2,919
	393	675	678	674	682	674	689	705	699	680	852	999
CWIP	29	20	6	13	12	24	19	105	198	261	137	96
Investments	489	325	491	471	585	665	790	886	806	843	1,028	1,048
	237	246	293	348	360	451	458	575	640	684	698	775
Total Assets	1,148	1,266	1,468	1,505	1,640	1,813	1,956	2,270	2,343	2,468	2,714	2,919

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	128	174	154	150	112	250	207	162	155	221	318	200
	-89	-73	-144	21	-121	-98	-77	-145	11	-17	-199	-110
	-48	-97	0	-169	-0	-142	-129	-10	-180	-202	-92	-93
Net Cash Flow	-9	4	11	1	-8	10	1	7	-14	2	26	-3
Free Cash Flow	83	-130	130	114	70	247	148	35	47	151	227	40
CFO/OP	96%	101%	92%	94%	81%	110%	90%	95%	93%	96%	129%	83%

Ratios

Consolidated / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	25	23	27	28	29	34	30	20	25	22	19	26
Inventory Days	132	134	148	166	184	180	189	210	183	216	186	182
Days Payable	94	84	81	101	82	101	68	94	99	103	102	106
Cash Conversion Cycle	64	72	94	93	131	113	152	135	109	135	103	102
Working Capital Days	11	21	23	29	45	40	48	45	48	53	33	41
ROCE %	21%	22%	21%	19%	17%	21%	22%	15%	13%	18%	16%	15%

Insights

In beta

Mar 2016

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Sep 2023

Mar 2025

Mar 2026

Zifi market share (Cefixime)
%

xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
			xxx.xx	x,xxx.xx	xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx	x,xxx.xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx		xx.xx	xx.xx
			xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
			xxx.xx	xxx.xx	xxx.xx	xxx.xx	xxx.xx
x,xxx	x,xxx			x,xxx		x,xxx	x,xxx
				xx.xx	xx.xx	xx.xx	xx.xx
						x.xx	x.xx
x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx	x.xx

Please log in to see hidden values.

Domestic formulation sales
INR crore

Electral market share (Oral Rehydration Salts)
%

API (Bulk Drugs) sales
INR crore

Export formulation sales
INR crore

Field force (Medical Representatives)
count

Enerzal market share (Energy Drinks)
%

Per Capita Per Month (PCPM) productivity
INR lakhs per MR per month

R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.66%	69.65%	69.65%
	2.42%	2.43%	2.65%	2.51%	2.62%	2.67%	2.56%	2.41%	2.43%	2.32%	2.40%	1.40%
	8.12%	7.76%	6.94%	6.72%	6.02%	6.08%	6.37%	7.17%	6.81%	6.27%	6.29%	6.31%
	19.80%	20.15%	20.76%	21.11%	21.71%	21.60%	21.42%	20.76%	21.10%	21.76%	21.65%	22.63%
No. of Shareholders	56,928	55,341	52,377	50,634	55,400	55,228	53,880	54,445	54,157	53,788	52,730	55,045

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	Jun 2026
	68.89%	69.07%	69.07%	69.24%	69.35%	69.36%	69.49%	69.66%	69.66%	69.65%	69.65%
	9.99%	9.57%	8.86%	5.65%	5.71%	4.52%	3.80%	2.65%	2.56%	2.40%	1.40%
	3.97%	4.06%	5.25%	5.61%	4.02%	5.86%	8.27%	6.94%	6.37%	6.29%	6.31%
	17.16%	17.30%	16.82%	19.50%	20.92%	20.27%	18.44%	20.76%	21.42%	21.65%	22.63%
No. of Shareholders	25,651	26,403	27,674	26,217	40,329	86,503	57,012	52,377	53,880	52,730	55,045

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Concalls

Nov 2023
Transcript PPT REC
Feb 2023

Transcript

AI Summary
PPT
Nov 2022
Transcript
PPT
Nov 2022
Transcript PPT
Aug 2022
Transcript PPT
May 2022
Transcript PPT
Feb 2022
Transcript
PPT
Dec 2021
Transcript
PPT
Jun 2017

Transcript

AI Summary
PPT
Nov 2016

Transcript

AI Summary
PPT
May 2016

Transcript

AI Summary
PPT